Lipitor verkäufe nach jahr

Executive summary: Lipitor (atorvastatin) is a large, mature statin with ongoing volume share driven by payer formulary coverage and a long generic runway starting in 2011. Near-term revenue is dominated by residual brand supply (including high-dose and "brand-generic mix" effects), while long-term sales are capped by generic penetration and evolving guideline-driven substitution to newer … Annual Sales of Lipitor reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. LIPITOR Market size is expected to reach USD 937.7 Mn by 2033 from USD 1,386.6 Mn in 2026, exhibiting a CAGR of -5.2% during the forecast period 2026-2033 This is a list of annual sales of patented medications per pharmaceutical group. Because it derives from 10-K data, drugs that have passed loss of exclusivity (LOE) will cease to be on this list. Top 10 Pharmaunternehmen nach prognostiziertem Umsatz¹ im Jahr 2023 (in Milliarden US-Dollar) Umsatz des Pharmaunternehmens Eli Lilly and Company in den Jahren 2007 bis 2025 (in Millionen US-Dollar) Weltweiter Umsatz von Pfizer mit dem Medikament Lyrica in den Jahren 2008 bis 2019 (in Millionen US-Dollar) Atorvastatin Market size was valued at $ 0.089 Billion in 2026 & is estimated to reach $ 0.15 Billion by 2032, exhibiting a CAGR of 7.71% from 2026-2032 Die Statistik zeigt den weltweiten Umsatz von Pfizer mit dem Produkt Lipitor in den Jahren 2003 bis einschließlich 2019. 07.10.2026 Der Arzneimittelmarkt in Zahlen Der Arzneimittelmarkt zielt auf die bedarfsgerechte Versorgung einer immer älter werdenden Gesellschaft mit sich stetig verändernden Krankheitsbildern. Dieser Markt ist hochkomplex und streng reguliert. Die aktuellen Daten und Fakten zeigen, dass das in Deutschland gut funktioniert. Humira, introduced by AbbVie in 2003, is expected to remain the drug with the highest lifetime revenue through 2024. Keytruda follows with a lifetime revenue of 213 billion U.S. dollars. LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident … Absatz von freiverkäuflichen Arznei- und Gesundheitsmitteln nach Vertriebsweg 2025 Absatz von freiverkäuflichen Arznei- und Gesundheitsmitteln in Deutschland nach Vertriebsweg im Jahr 2025 (in Millionen Packungseinheiten) Lipitor, the cholesterol-lowering medication that has become the gold standard of statins, continues to generate roughly $2 billion per year in sales for Pfizer, even though its patent expired eight years ago. The big picture: Almost all of Pfizer's Lipitor sales now come from China and other emerging markets. But Lipitor's ability to remain a blockbuster drug, even with so many generic … Mehrere Medien berichten über den Verkauf von 110 Millionen ADA durch Großanleger und blicken auf ein Cardano-Investment von vor einem Jahr zurück. LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident … The Global LIPITOR Market is estimated to be valued at USD 1,386.6 Mn in 2025 and is expected to reach USD 937.7 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of -5.4% from 2025 to 2032. The global LIPITOR market, once a dominant force in the pharmaceutical industry, is now experiencing slow and steady growth, driven by the ongoing demand for atorvastatin calcium, a widely … Infolgedessen verzeichnete Pfizer einen starken Rückgang der Lipitor-Verkäufe und verlor einen erheblichen Teil seines Marktanteils. 3. Tipps für Pharmaunternehmen, die vor der Patentklippe stehen Pharmaunternehmen können verschiedene Strategien anwenden, um die Auswirkungen von Patentabläufen abzumildern und ihre Marktposition zu behaupten. The Lipitor Market, valued at USD 1.38B in 2026, is projected to reach USD 2.03B by 2034, growing at a 4.9% CAGR. LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident … Nach der Indexierung im Jahr 2022 stieg der Wert der Aktien zwischenzeitlich auf fast 120 Euro. Nach einem fast kontinuierlichen Wertverlust von über 60 Prozent über gut zwei Jahre hinweg war Porsche das DAX-Unternehmen mit der geringsten Marktkapitalisierung. Dementsprechend erfolgte schließlich die Abstufung der Aktien. Lipitor was approved by the government in 1997, and while under patent protection it was the highest-selling drug of all time with worldwide sales of more than US$12 billion a year. Market Overview Global Atorvastatin Calcium Market size is expected to be worth around US$ 38.51 Billion by 2035 from US$ 15.83 Billion in 2025, growing at a CAGR of 9.3% during the forecast period from 2026 to 2035. In 2025, Europe led the market, achieving a share of over 39% and a revenue of US$ 6.17 Billion. Atorvastatin calcium is a widely prescribed lipid-lowering medication belonging to …